BACKGROUND: This study investigated whether single nucleotide polymorphisms (SNP) in genes within the catechol estrogen metabolism pathway altered the risk of breast cancer alone or in combination, as well as whether menopausal hormone therapy modified the effect of these SNPs on breast cancer risk. METHODS: In a population-based case-control study of breast cancer, 891 cases and 878 controls were genotyped for six functional SNPs in the COMT, CYP1B1, GSTM1, GSTP1, and GSTT1 genes. RESULTS: Women homozygous with the T allele in CYP1B1*2 (Ser(119); rs1056827) were at 1.69 (95% confidence interval, 1.17-2.46) times the risk of women homozygous with the G allele; women homozygous with the G allele in GSTP1 (Val(105); rs1695) were at 0.73 (95% confidence interval, 0.54-0.99) times the risk of breast cancer compared with women homozygous with the A allele. No other SNPs tested were associated with breast cancer to any appreciable degree. Potential gene-gene and gene-hormone therapy interactions were investigated. CONCLUSION: With the exception of GSTP1 and possibly CYP1B1*2, our findings do not provide support for the role of genetic variation in the catechol estrogen metabolism pathway and breast cancer risk in postmenopausal women.
BACKGROUND: This study investigated whether single nucleotide polymorphisms (SNP) in genes within the catechol estrogen metabolism pathway altered the risk of breast cancer alone or in combination, as well as whether menopausal hormone therapy modified the effect of these SNPs on breast cancer risk. METHODS: In a population-based case-control study of breast cancer, 891 cases and 878 controls were genotyped for six functional SNPs in the COMT, CYP1B1, GSTM1, GSTP1, and GSTT1 genes. RESULTS:Women homozygous with the T allele in CYP1B1*2 (Ser(119); rs1056827) were at 1.69 (95% confidence interval, 1.17-2.46) times the risk of women homozygous with the G allele; women homozygous with the G allele in GSTP1 (Val(105); rs1695) were at 0.73 (95% confidence interval, 0.54-0.99) times the risk of breast cancer compared with women homozygous with the A allele. No other SNPs tested were associated with breast cancer to any appreciable degree. Potential gene-gene and gene-hormone therapy interactions were investigated. CONCLUSION: With the exception of GSTP1 and possibly CYP1B1*2, our findings do not provide support for the role of genetic variation in the catechol estrogen metabolism pathway and breast cancer risk in postmenopausal women.
Authors: K Mitrunen; N Jourenkova; V Kataja; M Eskelinen; V M Kosma; S Benhamou; H Vainio; M Uusitupa; A Hirvonen Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-03 Impact factor: 4.254
Authors: Valentina Paracchini; Sara Raimondi; Inger T Gram; Daehee Kang; Neslihan A Kocabas; Vessela N Kristensen; Donghui Li; Fritz F Parl; Tove Rylander-Rudqvist; Pavel Soucek; Wei Zheng; Sara Wedren; Emanuela Taioli Journal: Am J Epidemiol Date: 2006-10-19 Impact factor: 4.897
Authors: C Sweeney; D C Farrow; S M Schwartz; D L Eaton; H Checkoway; T L Vaughan Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-04 Impact factor: 4.254
Authors: Julia Süllner; Claus Lattrich; Julia Häring; Regina Görse; Olaf Ortmann; Oliver Treeck Journal: Oncol Lett Date: 2011-09-16 Impact factor: 2.967
Authors: Kerryn W Reding; Chu Chen; Kimberly Lowe; David R Doody; Christopher S Carlson; Christina T Chen; John Houck; Linda K Weiss; Polly A Marchbanks; Leslie Bernstein; Robert Spirtas; Jill A McDonald; Brian L Strom; Ronald T Burkman; Michael S Simon; Jonathan M Liff; Janet R Daling; Kathleen E Malone Journal: Cancer Causes Control Date: 2012-03-15 Impact factor: 2.506
Authors: Anubha Saxena; Varinderpal S Dhillon; Mohammad Shahid; Hesham Saleh Khalil; Madhu Rani; Trinath Prasad DAS; Suresh Hedau; Arif Hussain; Raza Ali Naqvi; S V S Deo; N K Shukla; B C DAS; Syed Akhtar Husain Journal: Exp Ther Med Date: 2012-09-17 Impact factor: 2.447